FTD Trials
A Phase 2b randomised controlled trial of sodium selenate as a disease modifying treatment for probable behavioural variant fronto-temporal dementia
This study is investigating a new drug, sodium selenate, for the treatment of behavioural variant frontotemporal dementia (bvFTD).
Up to 120 patients with bvFTD will be recruited into the study. Half of the patients will receive 52 weeks of treatment with sodium selenate and the other half a placebo (a sugar pill). The main outcome of the study will be the change in brain volume over 52 weeks, comparing the treatment group to the placebo group. Additional outcomes will look at the overall safety and tolerability of the treatment, the levels of tau (a protein involved in the development of bvFTD) in the cerebrospinal fluid, the rate of cognitive decline and changes in behavioural symptoms observed in patients over the 52 weeks of treatment.
The study has sites in Melbourne and Sydney. For further information please email selenate@alfred.org.au
MRI scan highlighting change in brain volume over 12 months
Researchers from The University of Melbourne are conducting a study to test a mobile application designed for people with younger-onset dementia (YOD).
We are currently looking for:
• People living with dementia who had an onset of the symptoms before the age of 65
• With access to a smartphone or tablet
• With access to a computer with a camera and internet connection (As there will be two brief cognitive assessments via Zoom)
• With a support person
• Willing to use a mobile app for 15-20 minutes twice a week, for a total of 4 weeks
If you are a person with YOD or caring for a person with YOD and would like to receive more information about the study, please feel free to contact Julieta Sabates on sabatesj@student.unimelb.edu.au or A/Prof Alex Bahar-Fuchs on alex.bahar@student.unimelb.edu.au, or to write down your email address on this link https://www.surveymonkey.com/r/KXH7R29 and we will contact you shortly.